Send to printer »

GEN News Highlights : Sep 22, 2006

PsychoGenics Expands Huntington Disease Collaboration on Transgenic Mouse Models

PsychoGenics expanded its research collaboration with the High Q Foundation and CHDI to phenotype transgenic mouse models of Huntington disease (HD) and evaluate potential therapeutics in those models.

As part of this collaboration PsychoGenics developed standardized and validated protocols that include assessment of motor and cognitive behavior during disease progression in established transgenic mouse models of HD. Using these mouse models and an adaptive allocation approach to experiment design, whereby compounds are screened and actives are re-screened to increase the statistical power, PsychoGenics developed a high-throughput approach to compound screening, allowing the company to profile the effects of compounds on multiple behavioral domains.